Using videomicroscopy to predict bleeding risk in patients with bleeding disorders
Interest of Sublingual Videomicroscopy for the Prediction of Bleeding in Von Willebrand Disease and Other Constitutional Haemorrhagic Diseases
This study is testing if a new way to look at tiny blood vessels under the tongue can help predict bleeding risks in adults with von Willebrand disease and Glanzmann thrombasthenia.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Lille Academic / other |
| Locations | 1 site (Lille, Nord) |
| Trial ID | NCT04119908 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the use of sublingual videomicroscopy to analyze capillary density as a non-invasive method for predicting bleeding risk in patients with von Willebrand disease and Glanzmann thrombasthenia. By assessing the sublingual capillary bed, researchers hope to identify patients at higher risk of bleeding due to angiodysplasias. The study involves adult patients with significant forms of these conditions and includes blood sample collection for further analysis.
Who should consider this trial
Good fit: Ideal candidates are adults with significant von Willebrand disease, Glanzmann thrombasthenia, moderate to severe hemophilia A, or women carrying the hemophilia gene.
Not a fit: Patients who are minors, pregnant, or unable to provide consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to better risk assessment and management strategies for patients with bleeding disorders.
How similar studies have performed: While the use of videomicroscopy in this context is innovative, similar approaches in assessing bleeding risk have shown promise in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient with a significant form of von Willebrand disease (according to the inclusion criteria of the Willebrand Disease French Reference Center), a Glanzmann Thrombasthenia, a moderate to severe Haemophilia A or a woman carrying the hemophilia gene * Social insured patient Exclusion Criteria: * Minor patient * Refusal of consent * Person benefiting from a system of legal protection * Pregnant patient
Where this trial is running
Lille, Nord
- CHU de Lille — Lille, Nord, France (Recruiting)
Study contacts
- Principal investigator: Antoine Rauch, MD,PhD — University Hospital, Lille
- Study coordinator: Antoine Rauch, MD,PhD
- Email: antoine.rauch@chru-lille.fr
- Phone: 3 20445962 (poste 29673)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.